First there was the weird loss of smell and taste associated with COVID-19 infections. Then there was “COVID toes,” known as pernio or chilblains, and peculiar rashes. Now we have another unusual syndrome causing illness in children—Kawasaki disease. Many of the rashes have been thought to be due to a vasculitis, or blood vessel inflammation.
The management of infectious diseases in children involves many of the same therapeutic principles seen in adult medicine, but it is also complicated by challenges unique to this special patient population. These include a relative lack of evidence-based consensus guidelines, fewer agents approved by the FDA for use in children, altered pharmacokinetic parameters and unique drug toxicities. While these challenges call for extra effort and diligence, they also present unique opportunities to optimize antimicrobial therapy.
In recent years, decrease in global mortality and improvement in quality of life have been among the most significant progresses in child and adult health (1). In the field of pediatric infectious diseases, remarkable advances have been achieved in terms of reduction of incidence of childhood infectious diseases and associated morbidity and mortality.
“The five-second rule probably should become the zero-second rule,” said Dr. Roy M. Gulick, chief of the division of infectious diseases at Weill Cornell Medical College.
PKIDs mission is to educate the public about infectious diseases, the methods of prevention and transmission, the latest advances in medicine, and the elimination of social stigma borne by the infected.
Access to essential infectious disease and immunization resources
To promote the advancement of knowledge and expertise in the diagnosis, prevention and treatment of pediatric infectious disease in Asia by conducting seminars, workshops and other scientific meetings and to encourage collaborative national and multinational researches on pediatric infectious diseases of high priority.
To promote the exchange of information among people who have special experience in the field of paediatric infectious diseases (by organizing regular scientific meetings, forming international study groups and networks, participation in advisory boards of other societies, organization of symposia at other international congresses, and through joint publications by members’ publications in the Pediatric Infectious Diseases Journal and other journals).
The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.
The section seeks to attract manuscripts on all aspects of pediatric infectious diseases, ranging from infections within the community to hospital-acquired infections.
PIDS is the world's largest organization of professionals dedicated to the treatment, control and eradication of infectious diseases affecting children. Membership is comprised of physicians, doctoral-level scientists and others who have trained or are in training in infectious diseases or its related disciplines, and who are identified with the discipline of pediatric infectious diseases or related disciplines through clinical practice, research, teaching and/or administration activities.
The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research.
Find out what you need to know about all the common and not-so-common infections.